INTRODUCTION
============

Hyperkalaemia, i.e. excess of circulating potassium (K^+^), is a potentially life-threatening electrolyte disorder \[[@gfy249-B1]\]. Although it is agreed upon that there appears to be a U-shaped relationship between serum K^+^ and death \[[@gfy249-B2]\], there remains a controversy as to the exact level of K^+^ at which the clinician should become concerned and consider altering therapy such as the renin--angiotensin--aldosterone system (RAAS) blockade \[[@gfy249-B7]\]. The optimal serum K^+^ may depend on the underlying conditions. Maintenance of total body K^+^ homoeostasis is a major function of a healthy kidney. Chronic kidney disease (CKD), with subsequent failure to augment distal tubular K^+^ secretion, arises as one of the most important clinical predictors of hyperkalaemia occurrence \[[@gfy249-B6], [@gfy249-B11]\]. In addition to K^+^ retention, accompanying comorbidities and medications make CKD patients particularly prone to a state of chronic hyperkalaemia \[[@gfy249-B5], [@gfy249-B6]\].

Intriguingly, there is evidence suggesting that hyperkalaemia is a less threatening condition in CKD \[[@gfy249-B3], [@gfy249-B12]\], arguing adaptive mechanisms that render better tolerance to elevated K^+^ in circulation \[[@gfy249-B17]\]. Most of these studies are of small scale and they include high-risk patients. In clinical practice, chronic mild hyperkalaemia is often interpreted as the normal state in patients with advanced CKD \[[@gfy249-B6], [@gfy249-B18]\]. This study evaluates this hypothesis by formally estimating K^+^ distribution in relation to estimated glomerular filtration rate (eGFR) and by exploring K^+^ ranges that predict mortality across worse CKD severity stages in a large healthcare system. As a secondary objective, and because plasma is the predominant source of K^+^ assessment in Sweden, we explored whether the observed optimal ranges approximated to current clinical K^+^ thresholds.

MATERIALS AND METHODS
=====================

Data sources and study population
---------------------------------

Included individuals were selected from the Stockholm CREAtinine Measurements (SCREAM) project \[[@gfy249-B23]\], a healthcare utilization cohort from the region of Stockholm, Sweden. SCREAM included all laboratory tests and healthcare utilization data from any individual who had plasma creatinine measured at least once during 2006--11 \[[@gfy249-B23]\]. All standard laboratory tests performed for these individuals during that period were extracted; the data set was then linked to regional and national administrative databases with complete information on demographic data, healthcare use, diagnoses, validated renal outcomes, vital status and pharmacy-dispensed medications. The Regional Ethical Review Board in Stockholm approved the study.

Eligible patients for this study were all adult individuals (≥18 years old) with at least one plasma K^+^ measurement recorded in outpatient care between 2006 and 2011 with a concurrent plasma creatinine measurement (up to 1 year prior to index date). Implausible plasma creatinine (\<25 or \>1500 μmol/L) and plasma K^+^ (\>10 mmol/L) values were discarded, and if multiple measurements were recorded on the same day, then their median value was considered. We censored at migration from the county or 31 December 2011; we also discarded individuals undergoing maintenance dialysis. Finally, we sampled at random one measurement per individual and set the index date as the date in which such measurement occurred. Baseline demographics, comorbid history and drug use (up to 6 months before index date) were defined at that point. The detailed flow chart of selection process for this study is depicted in [Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S1](#sup1){ref-type="supplementary-material"}.

Biochemical assessments and study covariates
--------------------------------------------

Biochemical assessments were performed as part of healthcare encounters and by three different laboratories that provide services to the region \[[@gfy249-B23]\]. Inter- and intra-laboratory variation was considered minimal, as the three laboratories were frequently being audited for quality and harmonization. Plasma creatinine measurements were standardized to isotope dilution mass spectrometry. Creatinine was used to calculate eGFR using the 2009 CKD-EPI creatinine-based equation \[[@gfy249-B24]\], and categorized as \<30 (mL/min/1.73 m^2^, eGFR category G4--G5), between 30 and 60 (eGFR G3) or ≥60 (eGFR G1--G2). Scandinavian countries adopted in the early 2000s plasma as the standard source for K^+^ in healthcare \[[@gfy249-B25]\]. Plasma K^+^ tests accounted for 91% of all K^+^ measurements (the remaining being in serum) \[[@gfy249-B11]\] and were measured by potentiometric titration.

Other study covariates were age at index date and sex. Clinical history of comorbidities (listed in [Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S1](#sup1){ref-type="supplementary-material"}) was defined from relevant International Classification of Diseases, 10th edition codes by established algorithms \[[@gfy249-B26]\]; the use of selected K^+^-sparing medications (listed in [Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S2](#sup1){ref-type="supplementary-material"}) at index event was defined as a drug purchase during the 6 months before index date using Anatomical Therapeutic Chemical classification system codes.

Mortality outcomes
------------------

Mortality was ascertained via linkage with the Swedish living status registry that is updated monthly and has no loss to follow-up. The main study outcome was 90-day mortality; secondary outcomes were 180- and 365-day mortality.

K^+^ distribution within CKD strata
-----------------------------------

We modelled plasma K^+^ distribution using quantile regression that calculates the percentiles of the outcome distribution as a function of other covariates. We modelled 2.5, 50.0 and 97.5 percentiles, including all covariates (demographics, comorbidities and medications detailed above) present in at least 1% of individuals and all pairwise statistical interactions between age, sex and eGFR. eGFR and age were modelled by using restricted cubic splines, with knots at 15, 30, 45, 60, 90 mL/min/1.73 m^2^ and 45, 65, 75 years, respectively. Plasma K^+^ reference range (or normal range) was defined as the set of values where 95% of the population falls within (i.e. the interval between the 2.5th and 97.5th percentiles of the distribution). We predicted distribution ranges using the quantile regression models and predicted the percentiles under different combinations of eGFR categories, age categories, sex, comorbidities and drug use, setting the adjustment level for the remaining covariates to their median (or most frequent) value.

K^+^ ranges associated with mortality within CKD strata
-------------------------------------------------------

First, we modelled the association between K^+^ values (as a continuous variable) and mortality using Cox regression models. The concept of 'optimal' K^+^ range is based on concentrations or levels that are associated with optimal health or minimal risk. The limits are defined as those where the health risks exceed a certain threshold. In this study, K^+^ ranges were defined as the range of values within which the mortality risk, quantified via the predicted hazard ratio (HR) from the above-mentioned models for a given eGFR category, increased by no more than 50% or 100%. We considered ranges where the mortality risk increased by no more than 50% as clinically relevant, and ranges where the mortality risk increased by no more than 100% as our most conservative estimation of clinical ranges. The central point, and reference value of each safe range was the value that yielded the lowest predicted risk for each eGFR category. We modelled K^+^ using restricted cubic splines with five knots at default percentiles, and we included an interaction term with eGFR category to test for effect modification. We adjusted each model by eGFR value, demographics, comorbidities and drug use. At every step, we graphically assessed and found satisfying the proportional hazards assumption for the validation models by plotting Schoenfeld residuals against ranks of time.

As a sensitivity analysis, we repeated the random sampling of index K^+^ per individual generating 99 additional study data sets. We performed all analyses again on these 99 data sets and compared them to evaluate if the random sampling process influenced the robustness and consistency of our results.

Statistical analyses
--------------------

We present continuous variables as median with interquartile interval (IQI); categorical variables are presented as number with proportion. All data cleaning, tidying and statistical analyses were performed using R \[[@gfy249-B27]\].

RESULTS
=======

Descriptive characteristics
---------------------------

After applying inclusion and exclusion criteria ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S1](#sup1){ref-type="supplementary-material"}), we considered 831 760 participants with a median age of 55 years (IQI: 39--69) and 55% women. Median eGFR was 92 mL/min/1.73 m^2^ (77--106) and median plasma K^+^ was 4.00 mmol/L (3.80--4.20). As many as 752 403 (90.46%) individuals had an eGFR \>60 mL/min/1.73 m^2^; 70 403 (8.46%) were in eGFR category G3 and 8594 (1.08%) were in eGFR category G4--G5. History of cardiovascular disease was present in 13.29% of participants, 37.39% had hypertension, 9.35% had diabetes and 9.74% had cancer. As many as 19.67% individuals were on RAAS inhibitors (RAASi) and 15.90% were using non-steroidal anti-inflammatory drugs (NSAIDs). The remaining descriptive characteristics are presented in [Table 1](#gfy249-T1){ref-type="table"}, and these did not vary noticeably between the main data set and other 99 replicated data sets ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S3](#sup1){ref-type="supplementary-material"}).

###### 

Descriptive characteristics overall and by eGFR category

                                                    G1--G2                    G3                   G4--G5                 Overall
  ----------------------------------------- ----------------------- ---------------------- ---------------------- -----------------------
  Number of individuals                             752 403                 70 403                  8954                  831 760
  Age (years), median (IQI)                  52.20 (37.07--65.39)    80.73 (72.27--86.80)   83.28 (73.57--88.79)   55.01 (38.72--68.64)
   \<45                                         284 717 (37.84)          1007 (1.43)             251 (2.80)           285 975 (34.38)
   45--64                                       273 544 (36.36)          7384 (10.49)           941 (10.51)           281 869 (33.89)
   65--74                                       112 854 (15.00)         13 811 (19.62)          1287 (14.37)          127 952 (15.38)
   ≥75                                          81 288 (10.80)          48 201 (68.46)          6475 (72.31)          135 964 (16.35)
  Women                                         412 036 (54.76)         42 088 (59.78)          4835 (54.00)          458 959 (55.18)
  Serum creatinine (µmol/L), median (IQI)         70 (60--81)           106 (91--121)          200 (166--259)           72 (62--84)
  eGFR (mL/min/1.73 m^2^), median (IQI)      94.72 (82.40--107.90)   50.40 (42.95--55.79)   23.34 (17.55--27.14)   92.31 (77.45--106.24)
  Plasma K^+^ (mmol/L), median (IQI)           4.00 (3.80--4.20)      4.20 (3.90--4.40)      4.40 (4.00--4.80)       4.00 (3.80--4.20)
  History of kidney transplant                    344 (0.05)              498 (0.71)             230 (2.57)             1072 (0.13)
  Hypertension                                  244 512 (32.50)         58 178 (82.64)          8341 (93.15)          311 031 (37.39)
  Cardiovascular disease                         73 159 (9.72)          31 762 (45.11)          5624 (62.81)          110 545 (13.29)
   Cerebrovascular disease                       33 491 (4.45)          13 236 (18.80)          2180 (24.35)           48 907 (5.88)
   Heart failure                                 24 771 (3.29)          18 302 (26.00)          4003 (44.71)           47 076 (5.66)
   Myocardial infarction                         22 002 (2.92)           9837 (13.97)           2028 (22.65)           33 867 (4.07)
   Peripheral vascular disease                   13 662 (1.82)           6917 (9.82)            1411 (15.76)           21 990 (2.64)
  Diabetes mellitus                              61 013 (8.11)          14 089 (20.01)          2706 (30.22)           77 808 (9.35)
  Cancer                                         64 555 (8.58)          14 364 (20.40)          2096 (23.41)           81 015 (9.74)
  COPD                                           50 687 (6.74)           9309 (13.22)           1498 (16.73)           61 494 (7.39)
  Rheumatoid disease                             14 981 (1.99)           4737 (6.73)             719 (8.03)            20 437 (2.46)
  Liver disease                                  14 850 (1.97)           1530 (2.17)             334 (3.73)            16 714 (2.01)
  Dementia                                        9920 (1.32)            5437 (7.72)             805 (8.99)            16 162 (1.94)
  Peptic ulcer disease                           12 042 (1.60)           3207 (4.56)             713 (7.96)            15 962 (1.92)
  Hemiplegia/paraplegia                           4047 (0.54)             505 (0.72)             113 (1.26)             4665 (0.56)
  AIDS/HIV                                        975 (0.13)              39 (0.06)              13 (0.15)              1027 (0.12)
  NSAIDs                                        121 164 (16.10)         10 242 (14.55)           835 (9.33)           132 241 (15.90)
  RAASi                                         126 684 (16.84)         31 994 (45.44)          4912 (54.86)          163 590 (19.67)
  ACEi                                          76 656 (10.19)          19 031 (27.03)          3086 (34.47)          98 773 (11.88)
  ARBs                                           54 890 (7.30)          14 525 (20.63)          2357 (26.32)           71 772 (8.63)
  MRAs                                            9178 (1.22)            6833 (9.71)            1242 (13.87)           17 253 (2.07)

Values are represented as *n* (%) unless otherwise specified.

COPD, chronic obstructive pulmonary disease; AIDS/HIV, acquired immune deficiency syndrome/human immunodeficiency virus; ACEi, angiotensin-converting enzyme inhibitor; ARBs, angiotensin receptor blockers; MRAs, mineralocorticoid receptor antagonist.

K^+^ distribution within CKD strata
-----------------------------------

Median plasma K^+^ values and reference ranges \[95% confidence interval (CI)\] by eGFR strata are presented in Figure [1](#gfy249-F1){ref-type="fig"}A. Median K^+^ levels were higher with lower kidney function, with a noticeable point of inflexion at the level of 45 mL/min/1.73 m^2^. For instance, a median plasma K^+^ of 3.98 mmol/L was observed in participants with eGFR between 91 and 105 mL/min/1.73 m^2^ compared with median plasma K^+^ of 4.56 mmol/L in participants with eGFR ≤15 mL/min/1.73 m^2^ ([Table 2](#gfy249-T2){ref-type="table"}). The lower reference limit was rather stable across lower eGFR categories, but the upper reference limit increased with worse eGFR categories, from 4.45 for individuals with eGFR \>105 to 5.95 mmol/L for individuals with eGFR ≤15 mL/min/1.73 m^2^ ([Table 2](#gfy249-T2){ref-type="table"}). The distribution of plasma K^+^ values by eGFR strata is presented in [Figure 1B](#gfy249-F1){ref-type="fig"}, and it shows a gradual shift towards higher plasma K^+^ values across eGFR categories. Reference ranges by age, adjusting for renal function and all other covariates, were stable with minimal variation as age increased ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S2](#sup1){ref-type="supplementary-material"} and [Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S4](#sup1){ref-type="supplementary-material"}). The shift in K^+^ ranges in relation to kidney function was similarly observed when segregating results by age and sex ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S5](#sup1){ref-type="supplementary-material"} and [Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S3](#sup1){ref-type="supplementary-material"}).

![Reference ranges (95% CI) for plasma K^+^ by eGFR (**A**) and density distribution of plasma K^+^ by eGFR category (**B**). In (A), the red line represents the 50th percentile, and black lines represent 2.5th and 97.5th percentiles, with their corresponding 95% CIs in shadows. (A) The output of a quantile regression model adjusted by eGFR, age, sex, comorbidities (myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, dementia, rheumatoid disease, chronic obstructive pulmonary disease, peptic ulcer disease, liver disease, cancer, diabetes mellitus, hypertension) and ongoing medication (NSAIDs, angiotensin-converting enzyme inhibitor, angiotensin receptor blockers, mineralocorticoid receptor antagonists). eGFR and age were modelled by using restricted cubic splines, and all pairwise statistical interactions between eGFR, age and sex were included. ](gfy249f1){#gfy249-F1}

###### 

Median, 2.5th and 97.5th percentiles of K^+^ distribution per 15 mL/min/1.73 m^2^ increase in kidney function using quantile regression

  eGFR mL/min/1.73 m^2^    Median (2.5--97.5%)
  ----------------------- ---------------------
  Overall                   4.04 (3.33--4.79)
  \>105                     3.89 (3.29--4.46)
  91--105                   3.98 (3.40--4.59)
  76--90                    4.01 (3.44--4.63)
  61--75                    4.04 (3.43--4.72)
  46--60                    4.07 (3.33--4.91)
  31--45                    4.22 (3.32--5.27)
  16--30                    4.38 (3.33--5.57)
  ≤15                       4.43 (3.22--5.65)

The quantile regression model was adjusted by eGFR, age, sex, comorbidities (myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, dementia, rheumatoid disease, chronic obstructive pulmonary disease, peptic ulcer disease, liver disease, cancer, diabetes mellitus, hypertension) and medication use (NSAIDs, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists). eGFR and age were modelled by using restricted cubic splines, and all pairwise statistical interactions between eGFR, age and sex were included.

As a sensitivity analysis, we compared these ranges with those obtained by replicating the random K^+^ selection process 99 times more. [Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S6](#sup1){ref-type="supplementary-material"} shows the reference ranges obtained by selecting the mean and median extremities across all the replicates, the narrowest interval obtained and the widest interval obtained. The difference between the median value and normal ranges presented in the main analysis and those obtained from the replicates were considered as minimal.

Follow-up for mortality
-----------------------

During the first 90 days of follow-up, 11 833 participants died (1.42%). Furthermore, 20 615 (2.48%) and 33 869 (4.07%) participants died within 180 and 365 days, respectively. K^+^ values outside the previously estimated distribution range were associated with increased risk of mortality; multivariable-adjusted HRs ranged between 1.72 (95% CI 1.62--1.82) and 2.97 (95% CI 2.76--3.19), with greater effect sizes for short-term mortality outcomes ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S7](#sup1){ref-type="supplementary-material"}). Sensitivity analyses obtained by replicating the selection process showed consistent results in terms of magnitude and direction of the association ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S8](#sup1){ref-type="supplementary-material"}).

eGFR-specific K^+^ ranges based on risk of mortality
----------------------------------------------------

As expected, the absolute risk of mortality is higher in individuals with lower renal function ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S4](#sup1){ref-type="supplementary-material"}). The adjusted relative mortality risk associated with K^+^ levels by eGFR category is depicted in [Figure 2](#gfy249-F2){ref-type="fig"}. Overall, the U-shaped association was gradually flattened with lower eGFR strata and for each predetermined follow-up time (P for interaction \<0.001). [Table 3](#gfy249-T3){ref-type="table"} depicts K^+^ concentration associated with the minimum mortality risk across eGFR strata. Although the lowest 90-day mortality risk was observed for a plasma concentration of 4.02 mmol/L in individuals with normal renal function (G1--G2), this value went up to 4.34 mmol/L (8% increase) in individuals with eGFR G4 or more. The same pattern was observed throughout the different observation periods. This was accompanied by a widening in the K^+^ ranges that predicted different risk scenarios: whereas the lower K^+^ limit remained rather stable (between 3.4 and 3.7 mmol/L through all strata), the upper K^+^ limit presented larger differences with lower eGFR. For instance, in eGFR G1--G2, while the range where the 90-day mortality risk increased by no more than 100% was 3.45--4.94 mmol/L, it widened to 3.36--5.18 in G3 and 3.26--5.53 mmol/L in G4--G5. Sensitivity analyses showed similar results in the 99 random data set selections ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Tables S9--S11](#sup1){ref-type="supplementary-material"}), and a 'dose-dependent' association was also observed while further splitting the eGFR category G3 into G3a (eGFR \<60--45 mL/min/1.73 m^2^) and G3b (eGFR \<45--30 mL/min/1.73 m^2^) ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S5](#sup1){ref-type="supplementary-material"} and [Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S12](#sup1){ref-type="supplementary-material"}).

![Multivariable association between K^+^ levels and 90-, 180- and 365-day mortality, by eGFR category. Models are adjusted by eGFR category, eGFR value, age, sex, comorbidities (myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, dementia, rheumatoid disease, chronic obstructive pulmonary disease, peptic ulcer disease, liver disease, cancer, diabetes mellitus, hypertension) and ongoing medication (NSAIDs, angiotensin-converting enzyme inhibitor, angiotensin receptor blockers, mineralocorticoid receptor antagonists). K^+^ was modelled by using restricted cubic splines with five knots, and a statistical interaction between K^+^ and eGFR category was included.](gfy249f2){#gfy249-F2}

###### 

eGFR-specific plasma K^+^ for different scenarios of risk prediction

  eGFR category        Minimum risk   \<50% risk increase          \<100% risk increase
  ------------------- -------------- --------------------- -------------------------------------
  90-day mortality                                         
   G1--G2                  4.02           3.61--4.61                    3.45--4.94
   G3                      4.28           3.57--4.87                    3.36--5.18
   G4--G5                  4.34           3.50--5.09                    3.26--5.53
  180-day mortality                                        
   G1--G2                  4.01           3.57--4.69                    3.39--5.05
   G3                      4.24           3.52--4.94                    3.27--5.34
   G4--G5                  4.35           3.41--5.22                    3.21--5.75
  365-day mortality                                        
   G1--G2                  4.03           3.54--4.74                    3.33--5.11
   G3                      4.22           3.42--5.09                    3.14--5.59
   G4--G5                  4.31           3.33--5.37        [^a^](#tblfn4){ref-type="table-fn"}

Not available, upper limit of risk doubling not reached.

Models are adjusted by eGFR category, eGFR value, age, sex, comorbidities (myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, dementia, rheumatoid disease, chronic obstructive pulmonary disease, peptic ulcer disease, liver disease, cancer, diabetes mellitus, hypertension) and medication use (NSAIDs, angiotensin-converting enzyme inhibitor, angiotensin receptor blockers, mineralocorticoid receptor antagonists). K^+^ was modelled by using restricted cubic splines with five knots, and a statistical interaction between K^+^ and eGFR category was included. Reference ranges are computed by fixing all remaining covariates to their median (most frequent) value.

When applying the K^+^ range of 3.5--5.0 mmol/L, the HR for 90-day mortality associated with out of range K^+^ values was significantly lower (non-overlapping 95% CI) in patients with eGFR G4--G5 (1.73, 95% CI 1.51--1.95) when compared with eGFR G1--G2 (2.66, 95% CI 2.48--2.85). When applying our eGFR-specific ranges, the HR was similar across eGFR strata ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S6](#sup1){ref-type="supplementary-material"} and [Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S13](#sup1){ref-type="supplementary-material"}). A considerable proportion of individuals would be reclassified by our proposed eGFR-specific ranges ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S14](#sup1){ref-type="supplementary-material"}).

DISCUSSION
==========

The main findings of this large healthcare-based study are: (i) patients with CKD had progressively higher concentration of plasma K^+^; (ii) the association between plasma K^+^ and mortality was U-shaped, with the lowest mortality observed in the range of 4.0--4.3 mmol/L depending on the underlying kidney function; and (iii) K^+^ ranges for mortality prediction varied by underlying kidney function, being shifted upwards in individuals with moderate and severe/end-stage CKD. Thus, although our study supports the view that hyperkalaemia is better tolerated in CKD, it challenges the current use of a single clinical K^+^ range for all patients.

The kidney plays a fundamental role in K^+^ homoeostasis \[[@gfy249-B6]\], and our study convincingly showed an important shift in both crude and multivariable-adjusted plasma K^+^ distribution with lower eGFR. How this chronic K^+^ accumulation may influence clinical outcomes is not well known, but small-scale reports suggested hyperkalaemia to be a less threatening condition in CKD. These studies compare the mortality associations of current clinical K^+^ thresholds in patients with CKD: Einhorn *et al.* \[[@gfy249-B12]\] were the first to suggest a stronger association between hyperkalaemia and 1-day mortality among patients with normal renal function than among patients with CKD; patients with end-stage renal disease in the study by Nakhoul *et al.* \[[@gfy249-B15]\] also had lower death hazards with hyperkalaemia relative to the entire cohort; An *et al.* \[[@gfy249-B13]\] showed, in 923 consecutive hospital admissions, a graded decrease in risk of death among patients with extreme levels of hyperkalaemia as CKD stage worsened; finally, a prospective analysis of sustained hyperkalaemia and outcomes in 820 patients with creatinine clearance \<50 mL/min suggested that serum K^+^ in the ranges of 5.0--6.0 mmol/L was well tolerated and associated with lower mortality risk when compared with ≤4.0 mmol/L \[[@gfy249-B16]\]. Of note, similar effect differences were reported in acute myocardial infarction cohorts when comparing dialysis versus non-CKD patients with hyperkalaemia \[[@gfy249-B3], [@gfy249-B14]\]. We could indeed observe the same HR attenuation in our study when using the currently established single clinical thresholds.

Our study expands previous evidence with the novel demonstration that the U-shaped association between K^+^ and death flattens across worse CKD stages. Based on this flattening, we suggest K^+^ ranges for different scenarios of risk prediction, and show a clear gradual shift in the upper K^+^ threshold across stages of CKD. We note that our most conservative range estimation in individuals with normal kidney function (3.45--4.95 mmol/L for 90-day mortality risk) approximates to the currently accepted single threshold of 3.5--5.0 mmol/L. However, this same estimation suggests a difference of 0.5 mmol/L in the upper threshold of individuals with CKD G4--G5 (3.26--5.53 mmol/L). This is consequent with the biological plausibility of a physiological adaptation to chronic hyperkalaemia in these patients \[[@gfy249-B17]\]. Yet, our results disagree with the size effect attenuation reported in previous small studies \[[@gfy249-B16]\], and we note that plasma K^+^ \>5.5 mmol/L strongly and independently predicted mortality in all eGFR strata, suggesting that K^+^ concentrations in these ranges continue to deserve attention, strict monitoring and treatment to minimize adverse outcomes. Recently \[[@gfy249-B28]\], a meta-analysis of the CKD prognosis consortium reported no difference in the association between serum K^+^ and mortality by eGFR strata among 1.2 million participants from 27 international cohorts. The diversity of populations considered in that analysis (10 general population cohorts or healthcare extractions, 7 high cardiovascular risk cohorts and 10 CKD-referred cohorts) may hamper comparison with our results. Furthermore, this research question was not formally addressed, given serum K^+^ within each eGFR strata was compared against the same reference category (4.2 mmol/L) that is based on the lowest risk prediction for the whole population.

The mechanisms behind this possible adaptation to increased K^+^ in CKD are not well described and cannot be ascertained from our observational analyses. Of the possible mediators of the association between hyperkalaemia and death, cardiac arrhythmia caused by alteration in the transmembrane potential is probably the most relevant. K^+^ has a major role in maintaining the resting membrane potential, with implications in regulating transmission of nerve impulses and cardiac rhythm. In myocardial cells, there are about 10 different K^+^ ion channels that are responsible for the intricate maintenance of a stable resting membrane potential through repolarization of the cell \[[@gfy249-B29]\]. The K^+^ channels display different properties and movements of K^+^ are also influenced by other ions such as protons, calcium and magnesium. CKD patients may to some extent adapt to the higher K^+^ levels through different mechanisms (intestinal and tubular secretion), thereby controlling hyperkalaemia. Nonetheless, we are not aware of any studies showing adaptation to higher K^+^ levels in other cells, e.g. myocardiocytes. However, K^+^ ion channels of the myocardium are sensitive to endogenous factors and may change both the number and the functioning as a result of structural \[[@gfy249-B30], [@gfy249-B31]\] and environmental \[[@gfy249-B32], [@gfy249-B33]\] alterations. We hypothesize that similar mechanisms may take place in CKD patients by slowly increasing K^+^ levels that are already in the high normal range. Finally, because of the interdependence between K^+^, acidosis and calcium/magnesium, it would be interesting to determine whether, for instance, acidosis modulates the association between circulating K^+^ and subsequent mortality.

A second novelty in our study is the focus on plasma K^+^ determinations. Plasma K^+^ is becoming standard and preferred to serum in many countries, owing to its faster turn around and not being influenced by pre-analytical issues (such as thrombocytosis, tourniquet compression or violent sample handling, thus reducing the risk of false positives---e.g. pseudokalaemias) \[[@gfy249-B34]\]. Despite this, plasma K^+^ is not currently considered by clinical guidelines, which either refer to serum or do not make distinction between the sources of K^+^ determination \[[@gfy249-B7]\]. Our plasma-derived K^+^ ranges may potentially be helpful to estimate risk in clinics or regions that use this method.

These findings may have clinical implications. On one hand, we add robust evidence to ongoing discussions on the need to develop disease-specific 'optimal' K^+^ ranges \[[@gfy249-B35]\]. Although current clinical guidelines suggest maintaining K^+^ within a range of 3.50--5.00 mmol/L, observational studies exploring mortality-associated ranges in elderly \[[@gfy249-B2]\], and patients with myocardial infarction \[[@gfy249-B3]\] or hypertension \[[@gfy249-B4]\], suggest these ranges to be narrower, in the range of 3.5--4.5 mmol/L. Our less conservative (\<50% risk increase) observed range in individuals with normal kidney function (3.61--4.61 mmol/L for 90-day mortality) would agree with these studies, but again suggests a difference of 0.5 mmol/L in the upper threshold of individuals with CKD G4--G5 (3.50--5.09 mmol/L).

On the other hand, clinical guidelines recommend some clinical decisions based on these K^+^ thresholds, such as not to initiate RAAS blockade therapy when K^+^ is \>5.0 mmol/L \[[@gfy249-B7]\]. Given the widely demonstrated effectiveness of these therapies and our observed shift in K^+^ ranges, interventional studies and/or *post hoc* analyses of existing trials may be needed to re-evaluate these assumptions. Studies should ideally follow to confirm our findings and, specially, to report on serum K^+^ ranges across renal function categories. If we consider that serum K^+^ concentration can be typically 0.1--0.4 mmol/L higher than that measured in an anticoagulated plasma sample \[[@gfy249-B36]\], then this may have larger consequences in both the use of these therapies and the management of dyskalaemias in persons with CKD.

Our study was observational, and we recognize that despite the use of robust methods, there is residual/unknown confounding, and that the relationship between K^+^ and death may represent reverse causation. It is also conceivable that the relative importance of hyperkalaemia decrease with lower eGFR as the underlying absolute risk of mortality is larger and patients die from other causes. Hyperkalaemia is also less common in individuals with normal renal function. Hence, the increased risk of mortality in that group may be a proxy of severe acute illnesses that we may not have accounted for in the analysis (detection bias). Nevertheless, even if K^+^ is just a marker of illness, clinical ranges are useful to aid in clinical decisions and may still vary by CKD stage. As study strengths, SCREAM and the Swedish National Health registries contain uniquely detailed information, and we were able to extract reliable and complete data on K^+^ tests, comorbid illnesses, concomitant medication and date of death, thus overall strengthening the reliability of our findings.

To conclude, our study shows that individuals with CKD require higher plasma K^+^ to predict a mortality risk similar to that of persons with normal renal function. Although we hope that our efforts open discussions on the need for disease-specific as opposed to a single clinical K^+^ range for all patients, we note that physiological adaptation in CKD incompletely explains why mortality risk could be diminished once hyperkalaemia has been established. As recently discussed by Montford and Linas \[[@gfy249-B1]\], frequent metabolic derangements (such as metabolic acidosis) and structural heart disease (such atrial fibrillation or heart failure) in CKD patients should theoretically predispose them to more toxicity with hyperkalaemia due to lower arrhythmogenic potential. Trials that randomize patients with CKD to different K^+^ targets would be necessary to definitively establish the optimal range for maintaining K^+^ levels.
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